医学
肿瘤科
贝伐单抗
替莫唑胺
舒尼替尼
脑膜瘤
埃罗替尼
内科学
全身疗法
瑞戈非尼
放射治疗
癌症
化疗
外科
表皮生长因子受体
结直肠癌
乳腺癌
作者
Émilie Le Rhun,Sophie Taillibert,Marc C. Chamberlain
标识
DOI:10.1080/14737175.2016.1184087
摘要
Introduction: Meningioma comprise 20-30% of all primary brain tumors. Notwithstanding surgery and radiotherapy, a subset of patients will manifest recurrent meningioma. Systemic therapy is recommended only when further surgery and radiotherapy are not possible. No prospective study with a high level of evidence is available to inform as to recommendations regarding systemic therapy.Areas covered: We aim to summarize systemic therapies for recurrent meningioma.Expert commentary: Hydroxurea, temozolomide, irinotecan, the combination of cyclophosphamide/adriamycine/vincristine, interferon-alpha, somatostatin analogs, mifepristone, megestrol acetate, imatinib, erlotinib and gefitinib are considered as having limited efficacy. Potential activity of VEGF (vascular endothelial growth factor) inhibitors such as sunitinib, valatinib, and bevacizumab is suggested in small non-controlled studies and requires validation in randomized trials. The identification of new prognostic markers such as TERT promoter mutations and potential new therapeutic targets, such as KLF4, AKT1, TRAF7, and SMO mutations hopefully facilitate this endeavor.
科研通智能强力驱动
Strongly Powered by AbleSci AI